Ocugen Stock News

A host of worries pulled the broader market lower after the long holiday weekend.

NEW YORK , Feb. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, PHUN, HMHC, HOOK, and TGNA. Full story available on Benzinga.com

The FDA has lifted its clinical hold on Ocugen Inc's (NASDAQ: OCGN) investigational new drug application seeking approval to conduct testing of the COVID-19 vaccine Covaxin in the U.S. "We are pl

The FDA has lifted its clinical hold on Ocugen Inc''s (NASDAQ: OCGN ) investigational new drug application seeking approval to conduct testing of the COVID-19 vaccine Covaxin in the U.S. "We are pleased to be able to move our clinical program for Covaxin forward, which we hope will bring us closer to offering an alternative Covid-19 vaccine," said Dr. Shankar Musunuri, Full story available on Benzinga.com

The FDA lifted a clinical hold that had been preventing Ocugen from starting a U.S.-based phase 3 clinical study of its COVID-19 vaccine.

Ocugen (OCGN) shares have added ~16% in the pre-market on Tuesday after the company announced that the U.S

Gainers Digital World Acquisition Corp . (NASDAQ: DWAC ) rose 28.5% to $108.31 in pre-market trading. Just hours after launching on Sunday night in Apples App Store, Donald Trump''s new social media app Truth Social encountered a partial outage. Truth Social is an app created by Trump''s new company, Trump Media & Technology Group, which announced a SPAC merger with Digital World Acquisition in October. BRC Inc. (NYSE: BRCC ) rose 25.1% to $23.50 in pre-market trading after gaining around 4% on Friday. Phunware, Inc (NASDAQ: PHUN ) rose 18.8% to $3.78 in pre-market trading. Phunware, recently announced the launch of its PhunToken (PHTK) liquidity pool rewards program. Ocugen, Inc. (NASDAQ: OCGN ) rose 17.1% to $4.05 in pre-market trading. The FDA has lifted its clinical hold on Ocugens investigational new drug application seeking approval to conduct testing of the COVID-19 vaccine Covaxin in the U.S. Healthcare Capital Corp. (NASDAQ: HCCC ) shares rose 13.4% to $11.44 in pre-market trading.

Shares of OCGN stock are flying higher after the FDA lifted its clinical hold on Covaxin, the company's coronavirus drug candidate. The post OCGN Stock Alert: Why Is Ocugen Heating Up Today?

What you need to know about trading penny stocks on February 22nd The post Trading Penny Stocks? Top Stock Market News for February 22nd, 2022 appeared first on Penny Stocks to Buy, Picks, News and In

The stock price of Ocugen, Inc. (NASDAQ: OCGN) increased by over 17% pre-market today. This is why it happened.

Until the hype surrounding its Covid-19 vaccine candidate is no longer priced into shares, it's best to avoid OCGN stock. The post Despite an 80% Drop, Ocugen Stock Is Still Too Pricey appeared first

InvestorPlace - Stock Market News, Stock Advice & Trading Tips An interview with Dr. Anthony Fauci about the Covaxin vaccine makes you wonder why investors have any interest in Ocugen and OCGN stock. The post Ocugen Stock Finally Sunk to Penny Status, But That Doesnt Make It a Buy appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. Get in Now on Tiny $3 Forever Battery Stock Interested in Crypto? Read This First

InvestorPlace - Stock Market News, Stock Advice & Trading Tips OCGN stock is definitely out of favor on Wall Street, but fresh poll data and an imminent R&D hub acquisition should spur some optimism. The post Americans Appetite for Vaccine Options Bodes Well for Ocugen appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. Get in Now on Tiny $3 Forever Battery Stock Interested in Crypto? Read This First

An interview with Dr. Anthony Fauci about the Covaxin vaccine makes you wonder why investors have any interest in Ocugen and OCGN stock.  The post Ocugen Stock Finally Sunk to Penny Status, But That

OCGN stock is definitely out of favor on Wall Street, but fresh poll data and an imminent R&D hub acquisition should spur some optimism. The post Americans' Appetite for Vaccine Options Bodes Well for